Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Controversy

Equipoise, a term whose time (if it ever came) has surely gone

David L. Sackett
CMAJ October 03, 2000 163 (7) 835-836;
David L. Sackett
Dr. Sackett is Director of the Trout Research & Education Centre at Irish Lake, Markdale, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

I thank Drs. Shapiro and Glass for the spirit, as well as the letter, of their commentary. In the same collegial spirit I reply.

If a term is to do more good than harm in human affairs, it must pass at least the following 3 tests:

· Consistency: it must mean roughly the same thing to everybody who uses it.

· Reality: it must describe something that‚s real.

· Utility: it must be frequently employed to aid and justify decisions.

The term ”equipoise” fails all 3 tests.

Consistency: Published definitions of ”equipoise” vary wildly, and new, often-conflicting ones are still being generated that defeat attempts to distinguish any ”theoretical” versus ”clinical” distinction. Some users define it as a perfect balance of evidence and would ”take odds of 1:1 on a bet,”1 only to be contradicted by others to whom it means ”the data suggest but do not prove” efficacy and safety.2 Some permit its ownership by individual clinicians and patients,3 but a letter in this issue insists that equipoise, ”unlike uncertainty, can never be possessed by individual trialists.”4 Drs. Shapiro and Glass define their brand of equipoise as ”uncertainty that rests with the expert clinical community as a whole.”5 By employing my transparent, old-fashioned term (”uncertainty”) to define their opaque, newfangled one (”equipoise”) they render things wonderfully clear, but leave me wondering why on earth they cling to such an arcane, confusing word. Nonetheless, and despite the general confusion, we appear to be in agreement that, at the community level, uncertainty over the efficacy and safety of a treatment provides a proper basis for conducting a randomized controlled trial (RCT).

Reality: A recent report to the Health Technology Assessment Programme of Britain‚s National Health Service has summarized it best: ”There is some ingenuity in the equipoise theory, although its constraints seem bizarre if one tries to apply the theory in practice.6”

Utility: The term ”equipoise” just hasn‚t been found useful at the coal face. My PubMed search yielded only 52 hits for ”equipoise” (a text word that maps to no MeSH terms or trees at all), and none of them came from the reports of actual trials. On the other hand, a similar search yielded 292 860 hits for ”uncertainty,” and this word was commonly employed in primary reports of actual RCTs as justification for their execution. Moreover, ”uncertainty” maps to the MeSH tree of ”probability,” the first branch of which is Bayes‚ theorem (a formula for reassessing uncertainty in the face of new evidence)!

Our remaining area of disagreement, the issue of individual uncertainty, points to a double shame. First, we clinicians who accept the awful responsibility of caring for individual patients with their unique risks, responsiveness, values and expectations have simply failed to communicate key elements of our decision-making to some ethicists and methodologists who don‚t diagnose and treat individual patients. Second, and in part as a consequence of the first, the latter group frequently comes across as dismissing the crucial importance of trust in relations between clinicians and patients. Drs. Shapiro and Glass provide 2 glaring examples of the ethicist‚s failure to grasp the clinical realities. First, their definition of evidence-based health care stops with external evidence and ignores the other 2 of its 3 vital elements: clinical expertise and patients‚ values.7 Second, they insist that a clinician who is reasonably certain that one of the treatments that might be allocated to a particular patient would be inappropriate for that patient ”set aside his or her opinion, bias or ’certainty‚ in deference to the reasoned uncertainty that exists within the larger community of experts.”5 This command not only fails the test of reality (substantial proportions of ”eligible but not randomized” patients arrive at that state precisely because they and their clinicians are reasonably certain which treatment they want or need). It also is inconsistent with the parallel and vital protection of the patient‚s autonomy and right to refuse to be randomized on the basis of their opinion, bias or certainty. Even those who use the term ”equipoise” agree that it asks clinicians to violate trust in the physician‐patient relationship.8 I can‚t see the frontline clinicians and patients who actually carry out trials ever agreeing with the proponents of equipoise on this point.

Footnotes

  • 𝛃 Dr. Sackett responds to Drs. Shapiro and Glass.

    Competing interests: None declared.

References

  1. 1.↵
    Lilford RJ, Jackson J. Equipoise and the ethics of randomization. J R Soc Med 1995;88:552-9.
    OpenUrlFREE Full Text
  2. 2.↵
    Karlawish JHT, Lantos J. Community equipoise and the architecture of clinical research. Camb Q Healthc Ethics 1997;6:385-96.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Alderson P. Equipoise as a means of managing uncertainty: personal, communal and proxy. J Med Ethics 1996;22:135-9.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Fergusson D, Hébert P. Uncertainty and equipoise [letter]. CMAJ 2000; 163(7):807.
    OpenUrlFREE Full Text
  5. 5.↵
    Shapiro SH, Glass KC. Why Sackett‚s analysis of randomized controlled trials fails, but needn‚t. CMAJ 2000;163(7):834-5.
    OpenUrlFREE Full Text
  6. 6.↵
    Ashcroft RE, Chadwick DW, Clark SRL, Edwards RHT, Frith L, Hutton JL. Implications of socio-cultural contexts for the ethics of clinical trials. Health Technol Assess 1997;1:No.9.
  7. 7.↵
    Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn‚t. BMJ 1996;312:71-2.
    OpenUrlFREE Full Text
  8. 8.↵
    Chard JA, Lilford RJ. The use of equipoise in clinical trials. Soc Sci Med 1998;47:891-8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 163, Issue 7
3 Oct 2000
  • Table of Contents
  • Index by author
  • Canadian Adverse Drug Reaction Newsletter (879-886)

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Equipoise, a term whose time (if it ever came) has surely gone
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Equipoise, a term whose time (if it ever came) has surely gone
David L. Sackett
CMAJ Oct 2000, 163 (7) 835-836;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Equipoise, a term whose time (if it ever came) has surely gone
David L. Sackett
CMAJ Oct 2000, 163 (7) 835-836;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Protocol for a systematic scoping review of reasons given to justify the performance of randomised controlled trials
  • Uncertainty about clinical equipoise
  • Uncertainty about clinical equipoise
  • Uncertainty about clinical equipoise
  • Google Scholar

More in this TOC Section

  • The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed
  • Rebuttal
  • The analysis by Manuel and colleagues creates controversy with headlines, not data
Show more Controversy

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire